iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/18713579/
Monoclonal antibody treatments for multiple sclerosis - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Sep;8(5):419-26.
doi: 10.1007/s11910-008-0065-3.

Monoclonal antibody treatments for multiple sclerosis

John W Rose  1 , John Foley, Noel Carlson
Affiliations
Review

Monoclonal antibody treatments for multiple sclerosis

John W Rose et al. Curr Neurol Neurosci Rep. 2008 Sep.

Abstract

Monoclonal antibodies (MAbs) may have great potential as therapies for autoimmune diseases. Their development as treatments for multiple sclerosis (MS) is promising. Partially effective immunomodulatory therapies have been helpful for many MS patients; however, for patients failing these immunomodulatory treatments, MAbs are an important new treatment option. Currently, MAbs are approved by the US Food and Drug Administration for treatment of many conditions, including autoimmune diseases. Four MAbs that have been investigated as potential treatments for MS are reviewed in this article. Of these MAbs, natalizumab is approved for treatment of MS. The other three MAbs (alemtuzumab, rituximab, and daclizumab) are all promising therapies in development for treatment of MS. Adverse effects are relatively mild for these MAbs; however, care in administration and management of these agents is emphasized. Overall, these MAb therapies have great promise in the treatment of MS.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. N Engl J Med. 2006 Mar 2;354(9):911-23 - PubMed
    1. Neurology. 2007 Apr 17;68(16):1299-304 - PubMed
    1. N Engl J Med. 2008 Feb 7;358(6):647-8 - PubMed
    1. J Immunol. 1987 Jun 1;138(11):3771-5 - PubMed
    1. Blood. 2007 Jun 15;109(12):5399-406 - PubMed

MeSH terms

LinkOut - more resources